Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CVM Stock Forecast 2026-2027
$5.27
Current Price
$44.31M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CVM Price Targets
+1,038.5%
To High Target of $60.00
+706.5%
To Median Target of $42.50
+374.4%
To Low Target of $25.00
CVM Price Momentum
-10.1%
1 Week Change
-12.2%
1 Month Change
-57.2%
1 Year Change
+0.2%
Year-to-Date Change
-74.2%
From 52W High of $20.40
+166.2%
From 52W Low of $1.98
📊 TOP ANALYST CALLS
Did CVM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if CEL-SCI is one of their latest high-conviction picks.
Latest CVM Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, CVM has a bullish consensus with a median price target of $42.50 (ranging from $25.00 to $60.00). The overall analyst rating is N/A (N/A/10). Currently trading at $5.27, the median forecast implies a 706.5% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CVM Analyst Ratings
2
Buy
0
Hold
0
Sell
CVM Price Target Range
Low
$25.00
Average
$42.50
High
$60.00
Current: $5.27
Latest CVM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CVM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 12, 2023 | EF Hutton | Tony Butler | Buy | Reiterates | $10.00 |
| Mar 9, 2023 | EF Hutton | Tony Butler | Buy | Reiterates | $10.00 |
| Feb 17, 2023 | EF Hutton | Tony Butler | Buy | Assumes | $10.00 |
| Dec 29, 2022 | EF Hutton | Tim Moore | Buy | Maintains | $16.00 |
| Aug 25, 2022 | EF Hutton | Buy | Initiates | $N/A | |
| Apr 7, 2022 | EF Hutton | Buy | Initiates | $N/A | |
| Jan 13, 2020 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Jan 13, 2020 | H.C. Wainwright | Buy | Initiates | $N/A | |
| Feb 20, 2013 | Taglich Brothers | Speculative Buy | Initiates | $N/A | |
| Feb 13, 2013 | Chardan Capital | Buy | Initiates | $N/A | |
| Jan 14, 2013 | Laidlaw & Co. | Buy | Initiates | $N/A |
Cel-Sci Corporation (CVM) Competitors
The following stocks are similar to CEL-SCI based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cel-Sci Corporation (CVM) Financial Data
Cel-Sci Corporation has a market capitalization of $44.31M with a P/E ratio of -0.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -176.3%.
Valuation Metrics
Market Cap
$44.31M
Enterprise Value
$41.56M
P/E Ratio
-0.8x
PEG Ratio
-5.5x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+24.7%
Current Ratio
2.3x
Debt/Equity
58.8x
ROE
-176.3%
ROA
-56.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cel-Sci Corporation (CVM) Business Model
About Cel-Sci Corporation
What They Do
Develops immunotherapy products for various diseases.
Business Model
CEL-SCI Corporation generates revenue through the research, development, and commercialization of its immunotherapy products. The company focuses on activating the immune system to treat significant health issues, particularly in cancer care, with its lead product being Multikine.
Additional Information
Founded in 1983, CEL-SCI plays a critical role in the biotechnology sector by addressing unmet medical needs globally. Their innovative approach to immune-based therapies positions them as a key player in advancing treatment options for serious diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
0
CEO
Mr. Geert R. Kersten Esq.
Country
United States
IPO Year
1991
Website
cel-sci.comCel-Sci Corporation (CVM) Latest News & Analysis
Latest News
CEL-SCI Reports Fiscal 2025 Results
17 days ago
Quick Summary
CEL-SCI Corporation reports financial results for FY 2025 ending September 30, along with key clinical and corporate developments.
Why It Matters
Financial results and clinical updates from CEL-SCI Corporation can impact stock performance, investor sentiment, and future funding opportunities.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
CEL-SCI Corporation (NYSE American: CVM) CEO Geert Kersten will present at the LD Micro "Main Event" Investor Conference on October 21, 2025, at 9:30 a.m. Virtual registration is available.
Why It Matters
CEO Geert Kersten's presentation at a major investor conference highlights CEL-SCI's visibility and potential, which may influence stock performance and investor sentiment.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
CEL-SCI Corporation (NYSE American: CVM) CEO Geert Kersten will present at the LD Micro Investor Conference on October 21, 2025, at 9:30 a.m. PST in San Diego, CA.
Why It Matters
CEL-SCI's CEO presentation at a prominent investor conference may signal potential updates on their immunotherapy developments, influencing investor sentiment and stock performance.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
CEL-SCI has successfully closed a $10 million public offering for its Multikine product, as announced from Vienna, VA.
Why It Matters
CEL-SCI's $10 million public offering may impact its cash flow and funding for operations, signaling confidence in growth but also potential dilution for existing shareholders.
Source: Business Wire
Market Sentiment:
Neutral
CEL-SCI Announces Proposed Public Offering
4 months ago
Quick Summary
CEL-SCI Corporation (NYSE American: CVM) plans to conduct a public offering of common stock and/or pre-funded warrants, pending market conditions. No assurance on timing or terms is provided.
Why It Matters
CEL-SCI's public offering may dilute existing shares, impacting stock value. Market conditions will influence the offering's success and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
CEL-SCI has announced a public offering priced at $10 million.
Why It Matters
CEL-SCI's $10 million public offering could dilute existing shares, impacting stock value. It may also indicate the company's funding needs and growth strategy, influencing investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About CVM Stock
What is Cel-Sci Corporation's (CVM) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Cel-Sci Corporation (CVM) has a median price target of $42.50. The highest price target is $60.00 and the lowest is $25.00.
Is CVM stock a good investment in 2026?
According to current analyst ratings, CVM has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.27. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CVM stock?
Wall Street analysts predict CVM stock could reach $42.50 in the next 12 months. This represents a 706.5% increase from the current price of $5.27. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cel-Sci Corporation's business model?
CEL-SCI Corporation generates revenue through the research, development, and commercialization of its immunotherapy products. The company focuses on activating the immune system to treat significant health issues, particularly in cancer care, with its lead product being Multikine.
What is the highest forecasted price for CVM Cel-Sci Corporation?
The highest price target for CVM is $60.00 from at , which represents a 1,038.5% increase from the current price of $5.27.
What is the lowest forecasted price for CVM Cel-Sci Corporation?
The lowest price target for CVM is $25.00 from at , which represents a 374.4% increase from the current price of $5.27.
What is the overall CVM consensus from analysts for Cel-Sci Corporation?
The overall analyst consensus for CVM is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $42.50.
How accurate are CVM stock price projections?
Stock price projections, including those for Cel-Sci Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 8:33 AM UTC